No products in the cart.
FDA Approves First-Ever Treatment for Non-Cystic Fibrosis Bronchiectasis
Key Points: 1. First FDA-approved therapy for non-cystic fibrosis bronchiectasis; addresses a major unmet respiratory need. 2. Phase 3 data...
Pharma
![2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]](data:image/svg+xml;nitro-empty-id=NzAxOjEzMjY=-1;base64,PHN2ZyB2aWV3Qm94PSIwIDAgMSAxIiB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==)
2 Minute Medicine: Pharma Roundup – Landmark lung approval, billion-dollar obesity drug deal, oncology safety halt, and GSK’s China push [August 14 2025]
FDA Approves First-Ever Treatment for Non-Cystic Fibrosis Bronchiectasis Late last week, the U.S. Food and Drug Administration approved Insmed’s Brinsupri...
Use of pregabalin may increase risk of heart failure in geriatric patients
1. In patients aged 65 to 89 years of age with non-cancer chronic pain, use of pregabalin was associated with...
New-generation antiseizure medications are better tolerated for patients with epilepsy
1. Newer-generation antiseizure medications (ASMs) were better tolerated and more likely to be maintained than older ASMs. 2. Only 23%...
Nerandomilast slows decline in FVC in idiopathic pulmonary fibrosis
1. In this randomized trial, among patients with idiopathic pulmonary fibrosis (IPF), nerandomilast slowed the decline in the forced vital...
Nerandomilast slows FVC decline in progressive pulmonary fibrosis
1. In this randomized controlled trial, treatment with nerandomilast led to slower declines in forced vital capacity (FVC) in patients...
![2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]](data:image/svg+xml;nitro-empty-id=NzcxOjEzMzY=-1;base64,PHN2ZyB2aWV3Qm94PSIwIDAgMSAxIiB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==)
2 Minute Medicine: Pharma Roundup – Gastric Immunotherapy Gains, Prostate Pill Expansion, Five-Minute Myeloma Dosing, and Streamlined CAR-T Access [July 8th 2025]
Imfinzi Combo Cuts Gastric Cancer Risk by Twenty Nine Percent Earlier this week at the American Society of Clinical Oncology...
Approved label populations may be broader than trial populations for new drugs
1. In this cross-sectional study, approved label populations were broader overall compared to trial populations for new drugs in the...
AAV gene therapy shows durable benefit in hemophilia B
1. In this prospective cohort study, a single intravenous dose of scAAV2/8-LP1-hFIXco gene therapy in men with severe hemophilia B...
Commonly cited medication triggers may not increase risk of microscopic colitis among older adults
1. In this series of target trial emulations, several common medications were not found to significantly affect the risk of...
